Genomic Sequencing Examination of 733 HER2-amplified Main and metastatic breast tumours discovered considerable enrichment of mutations that activate RAS–MAPK signalling in advanced tumours treated with prior anti-HER2 therapies121. These mutations, together with NF1 and HER2 activating mutations, lead to resistance to tucatinib and neratinib. They’ll check with about your own https://www.directivepublications.org/journal-of-clinical-breast-cancer/